The sessions align with the yearlong theme selected by this year’s ACCC president, David R. Penberthy, MD, MBA, when he took the helm in March: “Leveraging Technology to Transform Cancer Care Delivery and the Patient Experience.”
Technology offers opportunities across cancer care—from diagnostics to precision medicine to better workforce management—and those who attend this week’s 39th National Oncology Conference of the Association of Community Cancer Centers (ACCC) will get to see, hear, and experience the next wave of solutions, when the meeting comes to West Palm Beach, Florida. The conference is taking place Wednesday through Friday at the Palm Beach Convention Center.
“Deconstructing Innovation” is the theme of this year’s meeting, which features preconference sessions on Wednesday ahead of the main conference. The sessions align with the yearlong theme selected by this year’s ACCC president, David R. Penberthy, MD, MBA, when he took the helm in March: “Leveraging Technology to Transform Cancer Care Delivery and the Patient Experience.”
For the first of Wednesday’s preconference sessions, Penberthy will team with his brother, Scott Penberthy, director of Applied AI at Google. Scott Penberthy, whose role centers on the application of artificial intelligence (AI) and information retrieval in health care at Google Cloud, will present, “The Age of Phenomics,” which is described as the “data-driven evolution of genomics that reasons about wellness transitions and their reversal from first principles.”
The main conference kicks off Thursday with keynote speaker Julie Holmes, a product and app inventor whose talk on technology and innovation is titled, “Little Big Bangs: Innovate and Improve in Challenging Times.” Holmes’ theme for the community oncology audience: improvements through micro-innovations, or everyday improvements, can add up to larger results that improve the lives of patients.
Friday’s featured speakers will discuss using data to mobilize the workforce and improve population health. They are Erica DeBoer, RN, MA, CCRN-K, CNL, chief nursing officer for Sanford Health, and Mike Koroscik, vice president, Oncology, for Allina Health Cancer Institute.
Thursday’s agenda offers shorter talks from winners of ACCC’s Innovator Awards, which recognize replicable programs that improve outcomes are cost-effective. Highlights from these programs include:
Friday’s morning agenda follows the themes of the featured speakers, including talks that that address today’s workforce challenges:
On both days of the main conference, the afternoons offer extended interactive workshops, which are designed to help care teams streamline processes and build positive change in the workplace. Most workshops are offered both days; they are:
Symptom Documentation Differences in Acute Cancer Care Suggest Sociodemographic Disparities
April 22nd 2025Researchers are calling for more targeted efforts to improve health equity after a new analysis revealed that cancer symptom documentation and burden vary across certain demographics.
Read More
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Rare Autoimmune Disorder Linked With Increased Risk of Certain Skin Cancers
April 21st 2025The risk of some skin cancers, including squamous cell carcinoma, basal cell carcinoma, and non-melanoma skin cancer, was particularly heightened among patients with severe mucous membrane pemphigoid.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Key Indicators of Myasthenia Gravis Disease Progression Reduced With Efgartigimod
April 18th 2025Research presented at the recent annual meeting of the Academy of Managed Care Pharmacy highlights outcomes among patients who have anti-acetylcholine receptor antibody-positive myasthenia gravis that include reduced exacerbations and need for immunoglobulin.
Read More